Tvardi Therapeutics (NASDAQ:TVRD) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Other research analysts also recently issued reports about the stock. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, July 8th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. HC Wainwright began coverage on shares of Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 price target for the company. Finally, BTIG Research cut their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Trading Up 1.9%

Shares of Tvardi Therapeutics stock opened at $1.87 on Friday. The firm has a market capitalization of $24.95 million, a PE ratio of -0.67 and a beta of 0.32. Tvardi Therapeutics has a 12 month low of $1.50 and a 12 month high of $43.65. The business’s 50-day moving average price is $2.27 and its 200-day moving average price is $2.91.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, analysts predict that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors have recently added to or reduced their stakes in TVRD. Quadrature Capital Ltd bought a new stake in shares of Tvardi Therapeutics in the 4th quarter worth approximately $90,000. Russell Investments Group Ltd. raised its holdings in shares of Tvardi Therapeutics by 1,351.5% during the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock valued at $69,000 after acquiring an additional 14,866 shares in the last quarter. HRT Financial LP bought a new position in shares of Tvardi Therapeutics during the fourth quarter valued at approximately $47,000. Goldman Sachs Group Inc. raised its holdings in shares of Tvardi Therapeutics by 37.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock valued at $142,000 after acquiring an additional 9,102 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics in the second quarter worth $80,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.